Literature DB >> 21596854

Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL.

Alan M Hanash1, Lucy W Kappel, Nury L Yim, Rebecca A Nejat, Gabrielle L Goldberg, Odette M Smith, Uttam K Rao, Lindsay Dykstra, Il-Kang Na, Amanda M Holland, Jarrod A Dudakov, Chen Liu, George F Murphy, Warren J Leonard, Glenn Heller, Marcel R M van den Brink.   

Abstract

IL-21 is a proinflammatory cytokine produced by Th17 cells. Abrogation of IL-21 signaling has recently been shown to reduce GVHD while retaining graft-versus-leukemia/lymphoma (GVL) responses. However, the mechanisms by which IL-21 may lead to a separation of GVHD and GVL remain incompletely understood. In a murine MHC-mismatched BM transplantation model, we observed that IL-21 receptor knockout (IL-21R KO) donor T cells mediate decreased systemic and gastrointestinal GVHD in recipients of a transplant. This reduction in GVHD was associated with expansion of transplanted donor regulatory T cells and with tissue-specific modulation of Th-cell function. IL-21R KO and wild-type donor T cells showed equivalent alloactivation, but IL-21R KO T cells showed decreased infiltration and inflammatory cytokine production within the mesenteric lymph nodes. However, Th-cell cytokine production was maintained peripherally, and IL-21R KO T cells mediated equivalent immunity against A20 and P815 hematopoietic tumors. In summary, abrogation of IL-21 signaling in donor T cells leads to tissue-specific modulation of immunity, such that gastrointestinal GVHD is reduced, but peripheral T-cell function and GVL capacity are retained. IL-21 is thus an exciting target for therapeutic intervention and improvement of clinical transplantation outcomes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596854      PMCID: PMC3138694          DOI: 10.1182/blood-2010-07-294785

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

1.  IL-21 regulates experimental colitis by modulating the balance between Treg and Th17 cells.

Authors:  Massimo C Fantini; Agelamaria Rizzo; Daniele Fina; Roberta Caruso; Christoph Becker; Markus F Neurath; Thomas T Macdonald; Francesco Pallone; Giovanni Monteleone
Journal:  Eur J Immunol       Date:  2007-11       Impact factor: 5.532

2.  Lack of IL-21 signal attenuates graft-versus-leukemia effect in the absence of CD8 T-cells.

Authors:  A Meguro; K Ozaki; K Hatanaka; I Oh; K Sudo; T Ohmori; H Matsu; R Tatara; K Sato; Y Sakata; S Nakae; W J Leonard; K Ozawa
Journal:  Bone Marrow Transplant       Date:  2011-01-24       Impact factor: 5.483

Review 3.  Interleukin-21: basic biology and implications for cancer and autoimmunity.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

4.  Organ-derived dendritic cells have differential effects on alloreactive T cells.

Authors:  Theo D Kim; Theis H Terwey; Johannes L Zakrzewski; David Suh; Adam A Kochman; Megan E Chen; Chris G King; Chiara Borsotti; Jeremy Grubin; Odette M Smith; Glenn Heller; Chen Liu; George F Murphy; Onder Alpdogan; Marcel R M van den Brink
Journal:  Blood       Date:  2008-01-04       Impact factor: 22.113

5.  IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells.

Authors:  Thomas Korn; Estelle Bettelli; Wenda Gao; Amit Awasthi; Anneli Jäger; Terry B Strom; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nature       Date:  2007-06-20       Impact factor: 49.962

6.  IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways.

Authors:  Liang Zhou; Ivaylo I Ivanov; Rosanne Spolski; Roy Min; Kevin Shenderov; Takeshi Egawa; David E Levy; Warren J Leonard; Dan R Littman
Journal:  Nat Immunol       Date:  2007-06-20       Impact factor: 25.606

Review 7.  The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer.

Authors:  Rosanne Spolski; Warren J Leonard
Journal:  Curr Opin Immunol       Date:  2008-06-12       Impact factor: 7.486

Review 8.  Interleukin-21: a new modulator of immunity, infection, and cancer.

Authors:  Katja Brandt; Prim B Singh; Silvia Bulfone-Paus; René Rückert
Journal:  Cytokine Growth Factor Rev       Date:  2007-05-16       Impact factor: 7.638

9.  IL-21 modulates CD4+ CD25+ regulatory T-cell homeostasis in experimental autoimmune encephalomyelitis.

Authors:  W-H Piao; Y H Jee; R L Liu; S W Coons; M Kala; M Collins; D A Young; D I Campagnolo; T L Vollmer; X-F Bai; A La Cava; F-D Shi
Journal:  Scand J Immunol       Date:  2008-01       Impact factor: 3.487

Review 10.  Interleukin 21: combination strategies for cancer therapy.

Authors:  Kresten Skak; Michael Kragh; Diana Hausman; Mark J Smyth; Pallavur V Sivakumar
Journal:  Nat Rev Drug Discov       Date:  2008-03       Impact factor: 84.694

View more
  38 in total

1.  Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Authors:  Keli L Hippen; Christoph Bucher; Dawn K Schirm; Amanda M Bearl; Ty Brender; Kathy A Mink; Kimberly S Waggie; Regis Peffault de Latour; Anne Janin; Julie M Curtsinger; Stacey R Dillon; Jeffrey S Miller; Gerard Socie; Bruce R Blazar
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

2.  Regulation of acute graft-versus-host disease by microRNA-155.

Authors:  Parvathi Ranganathan; Catherine E A Heaphy; Stefan Costinean; Nicole Stauffer; Caroline Na; Mehdi Hamadani; Ramasamy Santhanam; Charlene Mao; Patricia A Taylor; Sukhinder Sandhu; Gang He; Arwa Shana'ah; Gerard J Nuovo; Alessandro Lagana; Luciano Cascione; Susanna Obad; Oliver Broom; Sakari Kauppinen; John C Byrd; Michael Caligiuri; Danilo Perrotti; Gregg A Hadley; Guido Marcucci; Steven M Devine; Bruce R Blazar; Carlo M Croce; Ramiro Garzon
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

3.  Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding.

Authors:  Parvathi Ranganathan; Apollinaire Ngankeu; Nina C Zitzer; PierPaolo Leoncini; Xueyan Yu; Lucia Casadei; Kishore Challagundla; Dawn K Reichenbach; Sabrina Garman; Amy S Ruppert; Stefano Volinia; Jessica Hofstetter; Yvonne A Efebera; Steven M Devine; Bruce R Blazar; Muller Fabbri; Ramiro Garzon
Journal:  J Immunol       Date:  2017-02-03       Impact factor: 5.422

Review 4.  Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation.

Authors:  Cameron McDonald-Hyman; Laurence A Turka; Bruce R Blazar
Journal:  Sci Transl Med       Date:  2015-03-25       Impact factor: 17.956

5.  IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.

Authors:  Jaebok Choi; Edward D Ziga; Julie Ritchey; Lynne Collins; Julie L Prior; Matthew L Cooper; David Piwnica-Worms; John F DiPersio
Journal:  Blood       Date:  2012-09-12       Impact factor: 22.113

6.  Graft-versus-host disease after double-unit cord blood transplantation has unique features and an association with engrafting unit-to-recipient HLA match.

Authors:  D M Ponce; A Gonzales; M Lubin; H Castro-Malaspina; S Giralt; J D Goldberg; A M Hanash; A Jakubowski; R Jenq; E B Papadopoulos; M A Perales; M R M van den Brink; J W Young; F Boulad; R J O'Reilly; S Prockop; T N Small; A Scaradavou; N A Kernan; C E Stevens; J N Barker
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-14       Impact factor: 5.742

7.  Choline acetyltransferase-expressing T cells are required to control chronic viral infection.

Authors:  Maureen A Cox; Gordon S Duncan; Gloria H Y Lin; Benjamin E Steinberg; Lisa X Yu; Dirk Brenner; Luke N Buckler; Andrew J Elia; Andrew C Wakeham; Brian Nieman; Carmen Dominguez-Brauer; Alisha R Elford; Kyle T Gill; Shawn P Kubli; Jillian Haight; Thorsten Berger; Pamela S Ohashi; Kevin J Tracey; Peder S Olofsson; Tak W Mak
Journal:  Science       Date:  2019-02-08       Impact factor: 47.728

8.  IL-21 accelerates xenogeneic graft-versus-host disease correlated with increased B-cell proliferation.

Authors:  Xiaoran Wu; Yi Tan; Qiao Xing; Shengdian Wang
Journal:  Protein Cell       Date:  2013-11-10       Impact factor: 14.870

9.  Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity.

Authors:  Arnab Ghosh; Yildirim Dogan; Maxim Moroz; Amanda M Holland; Nury L Yim; Uttam K Rao; Lauren F Young; Daniel Tannenbaum; Durva Masih; Enrico Velardi; Jennifer J Tsai; Robert R Jenq; Olaf Penack; Alan M Hanash; Odette M Smith; Kelly Piersanti; Cecilia Lezcano; George F Murphy; Chen Liu; M Lia Palomba; Martin G Sauer; Michel Sadelain; Vladimir Ponomarev; Marcel R M van den Brink
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

Review 10.  Concise review: acute graft-versus-host disease: immunobiology, prevention, and treatment.

Authors:  Anthony D Sung; Nelson J Chao
Journal:  Stem Cells Transl Med       Date:  2012-12-19       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.